LP002 / Lepu Med - LARVOL DELTA

Perioperative chemotherapy with LP002, an anti-PD-L1 antibody, in patients with resectable gastric and gastroesophageal junction cancer: A prospective, open-label, phase Ib trial. (ASCO 2022) - P1 | "LP002 plus cisplatin and 5-fluorouracil was safe in pts with resectable gastric or GEJ cancer, and could be a new perioperative treatment option for PD-L1 positive disease. Pts are followed-up for survival outcomes."

Clinical • IO biomarker • P1 data • Anorexia • Endocrine Cancer • Endocrine Disorders • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Neuroendocrine Tumor • Oncology • Solid Tumor

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma (clinicaltrials.gov) - P1; N=63; Recruiting; Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.

Clinical • New P1 trial • Immune Modulation • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • PD-L1

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2; N=46; Recruiting; Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.

Clinical • Combination therapy • New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms (clinicaltrials.gov) - P1; N=94; Recruiting; Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.

Clinical • New P1 trial • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PD-L1